FDA puts partial hold on Gilead’s CD47 hopeful in AML
The FDA put a partial clinical hold on Gilead’s magrolimab for acute myeloid leukemia, a month after the company scrapped late-stage development of the CD47 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
